Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
9 pending office actions • 5 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
The Hospital for Sick Children is active in the Biotechnology & Pharmaceuticals technology area with 7 pending office actions. These actions are distributed across 7 distinct examiners, which means each pending application is being reviewed by a different individual. This variety of examiners can lead to different prosecution experiences for each matter in the portfolio.
The portfolio's work is spread across 5 distinct art units. This indicates that the hospital's biotechnology innovations are diverse enough to be categorized into five different technical areas by the patent office. PATEL, JAY M is the busiest examiner for the portfolio, with 1 pending office action. This examiner's workload is one of seven equal parts of the total pending actions.
The workload is evenly balanced, as the busiest examiner is responsible for 1 of the 7 total pending actions. This distribution ensures that no single examiner has a dominant influence on the portfolio's progress. Practitioners should be prepared to navigate the requirements of 5 distinct art units and the individual styles of seven separate examiners. This structure requires a highly coordinated strategy to manage the diverse technical and examiner-specific demands.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (11%) |
| §103 only | 1 (11%) |
| §112 only | 2 (22%) |
| Double-patenting + other | 3 (33%) |
| Multi-statute (no §101) | 2 (22%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PATEL, JAY M | 1 | 64.6% | +39.2% |
| COFFA, SERGIO | 1 | 61.1% | +32.5% |
| NICKOL, GARY B | 1 | 47.1% | +31.1% |
| CUNNINGCHEN, KATHLEEN MARY | 1 | 61.1% | +62.5% |
| PARK, EVELYN GRACE | 1 | 51.6% | +40.5% |
| XIAO, YAN | 1 | 67.3% | +52.7% |
| MELCHIOR, JAMES RYLAND | 1 | 63.0% | +38.5% |
| MARMOR II, CHARLES ALAN | 1 | 12.4% | +25.7% |
| MEYERING, SHABANA SHABBEER | 1 | 70.6% | +42.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18800528 | SYSTEM AND METHOD FOR CANCER-CELL SPECIFIC TRANSCRIPTION IDENTIFICATION | PATEL, JAY M | — |
| 18371847 | APPARATUS FOR AUTOMATED PAIN TESTING IN RODENTS | PARK, EVELYN GRACE | — |
| 18003256 | MAGNETICALLY ACTUATED CAPSULE | MARMOR II, CHARLES ALAN | — |
| 17598272 | COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS | MEYERING, SHABANA SHABBEER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18800528 | SYSTEM AND METHOD FOR CANCER-CELL SPECIFIC TRANSCRIPTION IDENTIFICATION | PATEL, JAY M | — |
| 18703101 | RECOMBINANT POLYPEPTIDE FOR DISRUPTING INTERACTION OF EAG2 AND KVß2 AND THERAPEUTIC APPLICATIONS THEREOF IN CANCER TREATMENT | COFFA, SERGIO | — |
| 18701187 | MODIFIED MULTABODY CONSTRUCTS, COMPOSITIONS, AND METHODS TARGETING SARS-COV-2 | NICKOL, GARY B | — |
| 18685711 | MOLECULES THAT BIND TO PROTOGENIN (PRTG) POLYPEPTIDES | CUNNINGCHEN, KATHLEEN MARY | — |
| 18371847 | APPARATUS FOR AUTOMATED PAIN TESTING IN RODENTS | PARK, EVELYN GRACE | — |
| 18263217 | MULTABODY CONSTRUCTS, COMPOSITIONS, AND METHODS | XIAO, YAN | — |
| 18253483 | POLYPEPTIDES TARGETING DR4 AND/OR DR5 AND RELATED COMPOSITIONS AND METHODS | MELCHIOR, JAMES RYLAND | — |
| 18003256 | MAGNETICALLY ACTUATED CAPSULE | MARMOR II, CHARLES ALAN | — |
| Art Unit | Apps |
|---|---|
| 3791 | 2 |
| 3681 | 1 |
| 1642 | 1 |
| 1658 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18800528 | SYSTEM AND METHOD FOR CANCER-CELL SPECIFIC TRANSCRIPTION IDENTIFICATION | PATEL, JAY M | 3681 | §101DP | Non-Final OA | — | Pending | Aug 12, 2024 |
| 18703101 | RECOMBINANT POLYPEPTIDE FOR DISRUPTING INTERACTION OF EAG2 AND KVß2 AND THERAPEUTIC APPLICATIONS THEREOF IN CANCER TREATMENT | COFFA, SERGIO | — | §112 | Final Rejection | — | Pending | Apr 19, 2024 |
| 18701187 | MODIFIED MULTABODY CONSTRUCTS, COMPOSITIONS, AND METHODS TARGETING SARS-COV-2 | NICKOL, GARY B | — | §103§112DP | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18685711 | MOLECULES THAT BIND TO PROTOGENIN (PRTG) POLYPEPTIDES | CUNNINGCHEN, KATHLEEN MARY | — | §112 | Non-Final OA | — | Pending | Feb 22, 2024 |
| 18371847 | APPARATUS FOR AUTOMATED PAIN TESTING IN RODENTS | PARK, EVELYN GRACE | 3791 | §102§103 | Final Rejection | — | Pending | Sep 22, 2023 |
| 18263217 | MULTABODY CONSTRUCTS, COMPOSITIONS, AND METHODS | XIAO, YAN | 1642 | §102§103§112DP | Non-Final OA | — | Pending | Jul 27, 2023 |
| 18253483 | POLYPEPTIDES TARGETING DR4 AND/OR DR5 AND RELATED COMPOSITIONS AND METHODS | MELCHIOR, JAMES RYLAND | 1658 | §102§103DP | Non-Final OA | — | Pending | May 18, 2023 |
| 18003256 | MAGNETICALLY ACTUATED CAPSULE | MARMOR II, CHARLES ALAN | 3791 | §103 | Final Rejection | — | Pending | Dec 23, 2022 |
| 17598272 | COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS | MEYERING, SHABANA SHABBEER | 1635 | §102§103 | Non-Final OA | — | Pending | Sep 26, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial